Artificial hormonal replacement cycles have no advantage over hyperstimulated cycles in a gamete intrafallopian transfer oocyte donation program.
OBJECTIVE
To evaluate if the previously reported increased implantation rates in hormonally replaced egg donation cycles relative to hyperstimulated IVF-ET cycles apply when GIFT is used. The increased implantation rates in the recipients have been attributed to the absence of the negative effects of hyperstimulation on endometrial receptivity.


METHODS
A prospective comparison of implantation rates in hyperstimulated and hormonally replaced cycles when GIFT was used in both the egg donors and their corresponding recipients.


METHODS
Excess mature oocytes from 35 women undergoing GIFT after controlled ovarian hyperstimulation (COH) were transferred into the fallopian tubes of 35 hormonally replaced women.


RESULTS
The male partners of all donors and recipients had normal semen parameters. The two groups did not differ significantly in the mean age, duration of infertility, and quality of eggs transferred. There was no statistically significant difference in the mean number of oocytes transferred per cycle between the donors and the recipients. The mean implantation rate per mature oocyte transferred was significantly higher in the donors (19.3%) than in the recipients (6.6%).


CONCLUSIONS
Our results with GIFT show higher implantation rates in hyperstimulated cycles than in hormonally replaced cycles. These results differ from those reported in IVF-ET that suggest an adverse effect of COH on implantation rates.
al-Khatib
R A
RA
College of Human Medicine, Department of Obstetrics and Gynecology, Michigan State University, Saginaw, USA.
Fakih
H
H
D000328:Adult; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D010064:Embryo Implantation; D004958:Estradiol / Q000627:therapeutic use*; D005260:Female; D015181:Gamete Intrafallopian Transfer; D006801:Humans; D008297:Male; D018587:Oocyte Donation; D010062:Ovulation Induction; D011247:Pregnancy; D011374:Progesterone / Q000627:therapeutic use*; D011446:Prospective Studies
D006063:Chorionic Gonadotropin; D011374:Progesterone; D004958:Estradiol